Cargando…

Tuberculin test conversion in patients with chronic inflammatory arthritis receiving biological therapy

OBJECTIVE: The blockade of inflammatory mediators produced by biological therapies is associated with an increased risk of opportunistic infections, as for example Mycobacterium tuberculosis (MT). Given the endemic situation of tuberculosis (TB) in some countries and immunosuppression/anergy of pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Cerda, Osvaldo Luis, de los Angeles Correa, María, Granel, Amelia, Marcos, Ana Ines, Giraldo, Claudia, Rillo, Oscar, Schneeberger, Emilce Edith, Citera, Gustavo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medical Research and Education Association 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459330/
https://www.ncbi.nlm.nih.gov/pubmed/30407165
http://dx.doi.org/10.5152/eurjrheum.2018.18096
_version_ 1783410163136331776
author Cerda, Osvaldo Luis
de los Angeles Correa, María
Granel, Amelia
Marcos, Ana Ines
Giraldo, Claudia
Rillo, Oscar
Schneeberger, Emilce Edith
Citera, Gustavo
author_facet Cerda, Osvaldo Luis
de los Angeles Correa, María
Granel, Amelia
Marcos, Ana Ines
Giraldo, Claudia
Rillo, Oscar
Schneeberger, Emilce Edith
Citera, Gustavo
author_sort Cerda, Osvaldo Luis
collection PubMed
description OBJECTIVE: The blockade of inflammatory mediators produced by biological therapies is associated with an increased risk of opportunistic infections, as for example Mycobacterium tuberculosis (MT). Given the endemic situation of tuberculosis (TB) in some countries and immunosuppression/anergy of patients with chronic inflammatory arthritis, we wonder whether it is necessary to monitor the MT infection after starting the biological treatment. To evaluate the frequency of the tuberculin skin test (TST) conversion and its association with an active TB infection and other disease variables. METHODS: Patients with rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), and spondyloarthritis (SpA) receiving treatment with anti-TNF, tocilizumab, and/or abatacept agents were included into the study. Patients had to have a negative TST (<5 mm) at the baseline, and a second TST was performed 2–22 months after the initiation of biologic therapy. The TST conversion was considered as a variation ≥5 mm between the two TSTs performed within an interval between 2 months and 2 years. RESULTS: A total of 85 patients were included into the study, and 78.8% were women, with a median schooling duration of 12 years. A total of 74.1% of patients had RA, 16.5% psoriatic arthritis, and 4.7% AIJ and ankylosing spondylitis. Regarding treatment, 75.3% received anti-TNF therapy (31.8% etanercept, 21.2% adalimumab, 17.6% infliximab, 3.5% golimumab, and 1.2% certolizumab), 15.3% tocilizumab, and 9.4% abatacept. Eight patients (9.4%) developed a TST conversion. The shift was more frequent in men (62.5%) than in women (37.5%) (p=0.009), and in those with a prolonged disease duration (X 226±109 vs X130±105 [p=0.017]). This association remained after adjusting for other variables. All patients who developed a TST conversion received prophylactic isoniazid, and only one patient with other risk factors developed active TB. CONCLUSION: The frequency of a TST conversion in patients with chronic inflammatory arthritis was low and was associated with male gender and longer disease duration.
format Online
Article
Text
id pubmed-6459330
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Medical Research and Education Association
record_format MEDLINE/PubMed
spelling pubmed-64593302019-04-19 Tuberculin test conversion in patients with chronic inflammatory arthritis receiving biological therapy Cerda, Osvaldo Luis de los Angeles Correa, María Granel, Amelia Marcos, Ana Ines Giraldo, Claudia Rillo, Oscar Schneeberger, Emilce Edith Citera, Gustavo Eur J Rheumatol Original Article OBJECTIVE: The blockade of inflammatory mediators produced by biological therapies is associated with an increased risk of opportunistic infections, as for example Mycobacterium tuberculosis (MT). Given the endemic situation of tuberculosis (TB) in some countries and immunosuppression/anergy of patients with chronic inflammatory arthritis, we wonder whether it is necessary to monitor the MT infection after starting the biological treatment. To evaluate the frequency of the tuberculin skin test (TST) conversion and its association with an active TB infection and other disease variables. METHODS: Patients with rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), and spondyloarthritis (SpA) receiving treatment with anti-TNF, tocilizumab, and/or abatacept agents were included into the study. Patients had to have a negative TST (<5 mm) at the baseline, and a second TST was performed 2–22 months after the initiation of biologic therapy. The TST conversion was considered as a variation ≥5 mm between the two TSTs performed within an interval between 2 months and 2 years. RESULTS: A total of 85 patients were included into the study, and 78.8% were women, with a median schooling duration of 12 years. A total of 74.1% of patients had RA, 16.5% psoriatic arthritis, and 4.7% AIJ and ankylosing spondylitis. Regarding treatment, 75.3% received anti-TNF therapy (31.8% etanercept, 21.2% adalimumab, 17.6% infliximab, 3.5% golimumab, and 1.2% certolizumab), 15.3% tocilizumab, and 9.4% abatacept. Eight patients (9.4%) developed a TST conversion. The shift was more frequent in men (62.5%) than in women (37.5%) (p=0.009), and in those with a prolonged disease duration (X 226±109 vs X130±105 [p=0.017]). This association remained after adjusting for other variables. All patients who developed a TST conversion received prophylactic isoniazid, and only one patient with other risk factors developed active TB. CONCLUSION: The frequency of a TST conversion in patients with chronic inflammatory arthritis was low and was associated with male gender and longer disease duration. Medical Research and Education Association 2019-01 2018-11-06 /pmc/articles/PMC6459330/ /pubmed/30407165 http://dx.doi.org/10.5152/eurjrheum.2018.18096 Text en © Copyright by 2019 Medical Research and Education Association http://creativecommons.org/licenses/by-nc/4.0/ Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
spellingShingle Original Article
Cerda, Osvaldo Luis
de los Angeles Correa, María
Granel, Amelia
Marcos, Ana Ines
Giraldo, Claudia
Rillo, Oscar
Schneeberger, Emilce Edith
Citera, Gustavo
Tuberculin test conversion in patients with chronic inflammatory arthritis receiving biological therapy
title Tuberculin test conversion in patients with chronic inflammatory arthritis receiving biological therapy
title_full Tuberculin test conversion in patients with chronic inflammatory arthritis receiving biological therapy
title_fullStr Tuberculin test conversion in patients with chronic inflammatory arthritis receiving biological therapy
title_full_unstemmed Tuberculin test conversion in patients with chronic inflammatory arthritis receiving biological therapy
title_short Tuberculin test conversion in patients with chronic inflammatory arthritis receiving biological therapy
title_sort tuberculin test conversion in patients with chronic inflammatory arthritis receiving biological therapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459330/
https://www.ncbi.nlm.nih.gov/pubmed/30407165
http://dx.doi.org/10.5152/eurjrheum.2018.18096
work_keys_str_mv AT cerdaosvaldoluis tuberculintestconversioninpatientswithchronicinflammatoryarthritisreceivingbiologicaltherapy
AT delosangelescorreamaria tuberculintestconversioninpatientswithchronicinflammatoryarthritisreceivingbiologicaltherapy
AT granelamelia tuberculintestconversioninpatientswithchronicinflammatoryarthritisreceivingbiologicaltherapy
AT marcosanaines tuberculintestconversioninpatientswithchronicinflammatoryarthritisreceivingbiologicaltherapy
AT giraldoclaudia tuberculintestconversioninpatientswithchronicinflammatoryarthritisreceivingbiologicaltherapy
AT rillooscar tuberculintestconversioninpatientswithchronicinflammatoryarthritisreceivingbiologicaltherapy
AT schneebergeremilceedith tuberculintestconversioninpatientswithchronicinflammatoryarthritisreceivingbiologicaltherapy
AT citeragustavo tuberculintestconversioninpatientswithchronicinflammatoryarthritisreceivingbiologicaltherapy